Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.

Zhaohu H, Xiao H, Hailin S, Feng H

Journal of diabetes research13 Aug 2022Cited by 10 (Europe PMC)

PMID35990242PMCIDPMC9381852DOI10.1155/2022/4126995PepBankPUB-35990242

Summary

ObjectiveWe aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the coronavirus disease 2019 (COVID-19) pandemic.MethodsT2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks. Changes in blood glucose and lipid levels, blood pressure, and body weight, as well as the occurrence of hypoglycaemia and other adverse events, were compared.Results309 patients completed the study (143 in liraglutide group and 166 in dapagliflozin group). After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from 8.80% ± 1.41% to 7.02% ± 1.05%, 10.41 ± 3.13 to 7.59 ± 2.16 mmol/L, and 17.90 ± 4.39 to 10.12 ± 2.47 mmol/L, respectively, in the dapagliflozin group, and from 8.92% ± 1.49% to 6.78% ± 1.00%, 10.04 ± 2.99 to 7.20 ± 1.63 mmol/L, and 17.30 ± 4.39 to 10.13 ± 4.15 mmol/L, respectively, in the liraglutide group. Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different. Systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) level significantly decreased from 144.1 ± 19.1 to 139.7 ± 16.2 mmHg (p = 0.001) and from 3.21 ± 0.94 to 2.98 ± 0.89 mmol/L (p = 0.014), respectively, in the dapagliflozin group. After COVID-19 outbreak, the number of patients taking sleep-promoting drugs increased from 4.9% to 9.4% (p = 0.029).ConclusionsLiraglutide and dapagliflozin had strong hypoglycaemic effects in patients with overweight or obesity and T2DM at the beginning of the COVID-19 pandemic. Dapagliflozin may be beneficial in improving SBP and LDL-C levels; however, further research is warranted.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, the change in HbA1c did not differ significantly between liraglutide and dapagliflozin.
In plain wordsIn people with overweight or obesity and type 2 diabetes, HbA1c changed by a similar amount with liraglutide and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change, liraglutide versus dapagliflozin
Study
n = 309
Comparator
Dapagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different.
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024204
02HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, the change in fasting plasma glucose did not differ significantly between liraglutide and dapagliflozin.
In plain wordsIn people with overweight or obesity and type 2 diabetes, fasting blood sugar changed by a similar amount with liraglutide and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose change, liraglutide versus dapagliflozin
Study
n = 309
Comparator
Dapagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different.
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024205
03HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, the change in 2-h postprandial glucose did not differ significantly between liraglutide and dapagliflozin.
In plain wordsIn people with overweight or obesity and type 2 diabetes, blood sugar after meals changed by a similar amount with liraglutide and dapagliflozin.
Peptide
Liraglutide
Outcome
No significant change2-h postprandial glucose change, liraglutide versus dapagliflozin
Study
n = 309
Comparator
Dapagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different.
1 context sentence(design, population, supporting numbers)
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024206
04HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, HbA1c decreased significantly from 8.92% to 6.78% with liraglutide over 24 weeks.
In plain wordsIn people with overweight or obesity and type 2 diabetes, HbA1c fell after 24 weeks of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at 24 weeks
Study
n = 143
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
HbA1c
8.92%
liraglutide, baseline
HbA1c
6.78%
liraglutide, 24 weeks
Source sentences
Summary
and from 8.92% ± 1.49% to 6.78% ± 1.00%
2 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024201
05HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, fasting plasma glucose decreased significantly from 10.04 to 7.20 mmol/L with liraglutide over 24 weeks.
In plain wordsIn people with overweight or obesity and type 2 diabetes, fasting blood sugar fell after 24 weeks of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change at 24 weeks
Study
n = 143
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
FPG
10.04 mmol/L
liraglutide, baseline
FPG
7.2 mmol/L
liraglutide, 24 weeks
Source sentences
Summary
10.04 ± 2.99 to 7.20 ± 1.63 mmol/L
2 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024202
06HumanRandomized controlled trialEfficacy outcome
In patients with overweight or obesity and type 2 diabetes, 2-h postprandial glucose decreased significantly from 17.30 to 10.13 mmol/L with liraglutide over 24 weeks.
In plain wordsIn people with overweight or obesity and type 2 diabetes, blood sugar after meals fell after 24 weeks of liraglutide.
Peptide
Liraglutide
Outcome
Decrease2-h postprandial glucose change at 24 weeks
Study
n = 143
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
2hPG
17.3 mmol/L
liraglutide, baseline
2hPG
10.13 mmol/L
liraglutide, 24 weeks
Source sentences
Summary
17.30 ± 4.39 to 10.13 ± 4.15 mmol/L, respectively, in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from
Summary · context
T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks.
Show in the study text Report a problemFND-3599024203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.